No response: recommended time points of assessment
| No response . | Imatinib-treated patients, mo* . |
|---|---|
| Less than CHR | 3 |
| No CgR (Ph+ > 95%) | 6 |
| Less than PCgR (Ph+ > 35%) | 12 |
| Less than CCgR (Ph+ > 0%) | 18 |
| No response . | Imatinib-treated patients, mo* . |
|---|---|
| Less than CHR | 3 |
| No CgR (Ph+ > 95%) | 6 |
| Less than PCgR (Ph+ > 35%) | 12 |
| Less than CCgR (Ph+ > 0%) | 18 |
The time lines refer to the allocation of study treatment and were published for patients treated by imatinib frontline. For reasons of comparability in a given trial and between trials, these recommendations should also be applied to patients given a treatment other than imatinib.
Adapted from Baccarani et al.20